CEVEC: CAPĀ® Derived Recombinant C1 Inhibitor Matches BerinertĀ® in Animal Study

Cologne, Germany, February 2, 2015
CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology, today announced a major milestone regarding its recombinant human CAP® cell derived C1 Esterase Inhibitor (C1Inh).

CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than plasma derived C1 Inh. To achieve this excellent protein quality of the recombinant C1Inh, new glycosylation optimized CAP-GO cells were developed at CEVEC. This result, in combination with previously shown excellent specific activities of CAP derived C1 Inh and commercially attractive production yields using CAP-GO cells, paves now the way to develop a safer and more economic therapy for acute and prophylactic HAE indications.

CAP for Protein Production


CAP and CAP-T Cells exhibit exceptional yields for complex proteins and antibodies. Authentic human-like post-translational modifications allow for higher specific activities and more cost-effective large scale productions of therapeutic molecules. A unique advantage of the transiently protein producing CAP-T Cells and the stably producing CAP Cells are identical and highest product qualities provided by an isogenic cellular background.


CAP for Vaccine Production


CAP Cells exhibit key advantages in the field of vaccine development: adapted to animal component free suspension culture the human amniocyte derived cells propagate a very broad range of clinically relevant human viruses at high titers. Non-tumorous origin, development of the cell line under guidance of ethical advisory committees and a fully documented history from donor to Master Cell Bank position CAP as a versatile mammalian expression host.


Clinical Material


CEVEC is your contract manufacturer of choice for cGMP production in CAP Cells.
CAP-derived clinical material can be provided for phase I-II studies and we produce your desired protein, vaccine, virus or gene therapy vector at extraordinary pace and competitive pricing through our CAP CMO Joint Venture with Genibet in Lisbon/Portugal.